| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 386.06 | 11.8% |
| Total Income | 393.58 | 11.7% |
| Expenditure | 332.35 | 5.1% |
| PBT | 61.23 | 69.9% |
| Net Profit | 45.25 | 54.8% |
| OPM | 23.25% | 5.21pp |
| NPM | 11.50% | 3.20pp |
| EPS | 8.70 | 52.9% |
Metropolis Healthcare Reports 23% Revenue Growth to INR 386 Crore in Q1FY26; PAT Up 19% YoY
07 Aug 2025 · 7 Aug 2025, 05:42 pm
Summary
Metropolis Healthcare, led by Ameera Shah, has reported a 23% YoY revenue growth to INR 386 Crore and a 19% YoY increase in PAT for Q1FY26. The company's patient and test volumes grew by 11% and 12% YoY, respectively. Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11% and 10% YoY. Specialty Diagnostics recorded the highest revenue growth at 32%. TruHealth wellness & illness bundled portfolio grew by 24%. The company's geographic footprint continues to expand, with North India's revenue contribution rising to 17%.
Key Highlights
- 1
Q1FY26 revenue grew by 23% YoY to INR 386 Crore
- 2
PAT increased by 19% YoY
- 3
Patient and test volumes grew by 11% and 12% YoY, respectively
- 4
Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11% and 10% YoY
- 5
Specialty Diagnostics recorded the highest revenue growth at 32%
- 6
TruHealth wellness & illness bundled portfolio grew by 24%
- 7
North India's revenue contribution rose to 17%
- 8
Tier III cities registered a revenue growth of 17%
Management Comments
Ameera Shah
Rising health awareness is fuelling demand for advanced diagnostics across prevention, wellness, and complex illness detection. These trends are expanding the formal diagnostics market and creating a broader revenue opportunities across industry players. Encouragingly, the market is stabilizing, with reduced pricing pressures and a stronger focus on Clinical quality and trust. At Metropolis, we continue to focus on high-value and complex testing, where accuracy, scientific excellence, and deep domain expertise are critical. Our recent acquisitions have strengthened our presence in specialised diagnostics, opening up premium growth opportunities and enhancing revenue quality. With sustained investments in Specialty Diagnostics, Genomics, and our Centers of Excellence, we are building a differentiated and future-ready healthcare enterprise that is well- positioned for long-term value creation.
Informational and educational content only. Not investment advice.